Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population. Insights From the ARIC (Atherosclerosis Risk in Communities) Study

Journal of the American College of Cardiology

Volumn 54, Issue 25, 2009, Pages 2388-2395

  Yang, Eric Y ^a,b   Nambi, Vijay ^a,b   Tang, Zhengzheng ^d   Virani, Salim S ^a,b   Boerwinkle, Eric ^c   Hoogeveen, Ron C ^a,b   Astor, Brad C ^e   Mosley, Thomas H ^f   Coresh, Josef ^e   Chambless, Lloyd ^d   Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d IL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

ARIC; cardiovascular disease; hs CRP; LDL C; lipids

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

AGE FACTORS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; UNITED STATES;

EID: 71649114494     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.006     Document Type: Article

References (15)

1. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
2. Spatz E.S., Canavan M.E., and Desai M.M. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2 (2009) 41-48
3. Michos E.D., and Blumenthal R.S. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 53 (2009) 931-935
4. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am J Epidemiol 129 (1989) 687-702
5. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 (2001) 418-425
6. Toole J.F., Chambless L.E., Heiss G., Tyroler H.A., and Paton C.C. Prevalence of stroke and transient ischemic attacks in the Atherosclerosis Risk in Communities (ARIC) study. Ann Epidemiol 3 (1993) 500-503
7. White A.D., Folsom A.R., Chambless L.E., et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study: methods and initial two years' experience. J Clin Epidemiol 49 (1996) 223-233
8. Rosamond W.D., Chambless L.E., Folsom A.R., et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 339 (1998) 861-867
9. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
10. Chambless L.E., Folsom A.R., Sharrett A.R., et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol 56 (2003) 880-890
11. Folsom A.R., Chambless L.E., Duncan B.B., Gilbert A.C., and Pankow J.S. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26 (2003) 2777-2784
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
13. Hlatky M.A. Expanding the orbit of primary prevention-moving beyond JUPITER. N Engl J Med 359 (2008) 2280-2282
14. Ridker P.M., Rifai N., Pfeffer M.A., et al., Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98 (1998) 839-844
15. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965